NCT06234605 - A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 29, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2027

Conditions

Renal Cell Carcinoma

Interventions

DRUG

HC-7366

HC-7366 is a novel, orally administered, highly selective and potent general control nonderepressible 2 (GCN2) kinase activator.

DRUG

Belzutifan

Belzutifan is a potent and selective HIF-2α inhibitor

Trial Locations (15)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

22031

RECRUITING

Virginia Cancer Specialists, Fairfax

37203

RECRUITING

SCRI Oncology Partners, Nashville

44106

RECRUITING

University Hospitals Cleveland Medical Center, Cleveland

44195

RECRUITING

Cleveland Clinic, Cleveland

53705

RECRUITING

University of Wisconsin - Carbone Cancer Center, Madison

55101

RECRUITING

HealthPartners Cancer Research Center, Saint Paul

63110

RECRUITING

Washington University School of Medicine, St Louis

75246

RECRUITING

Texas Oncology, Dallas

80124

RECRUITING

Rocky Mountain Cancer Centers, LLP, Lone Tree

85719

RECRUITING

University of Arizona Cancer Center, Tucson

90048

RECRUITING

Cedars-Sinai Medical Center, Los Angeles

92093

RECRUITING

University of California San Diego Moores Cancer Center, La Jolla

97213

RECRUITING

Providence Cancer Institute, Portland

98104

RECRUITING

Swedish Medical Center, Seattle